Online first
Clinical vignette
Published online: 2024-06-03

open access

Page views 40
Article views/downloads 30
Get Citation

Connect on Social Media

Connect on Social Media

Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!

Kamel Debbi1, Gokoulakrichenane Loganadane1, Louise Roulin23, Karim Belhadj23, Chahrazed Boukhobza1, Amira Saoudi1, Noémie Grellier1, Yazid Belkacemi14

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. Murray Brunt A, Haviland JS, Wheatley DA, et al. FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020; 395(10237): 1613–1626.
  2. Brunt AM, Wheatley D, Yarnold J, et al. FAST-Forward Trial Management Group. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016; 120(1): 114–118.
  3. Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma. Cancer. 2019; 125(14): 2364–2382.
  4. Kastritis E, Palladini G, Minnema MC, et al. ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021; 385(1): 46–58.
  5. Elhassadi E, Murphy M, Hacking D, et al. Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. Clin Case Rep. 2018; 6(4): 723–728.
  6. Resende Salgado L, Wang S, Adler A, et al. The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era. Adv Radiat Oncol. 2019; 4(1): 112–117.
  7. Engelhardt M, Wäsch R, Reinhardt H, Kleber M. Pomalidomide. In: Martens UM. ed. Small molecules in oncology. Springer 2014: 359–372.
  8. Barlas C, Dağdelen M, Elverdi T, et al. Successful Treatment Of Bulky Abdominal Plasmacytomas With Radiotherapy and Pomalidomide. East J Med. 2022; 27(2): 330–332.



Reports of Practical Oncology and Radiotherapy